ホーム>>Signaling Pathways>> Proteases>> E1/E2/E3 Enzyme>>HB007

HB007

カタログ番号GC63002

HB007 は小さなユビキチン関連修飾子 1 (SUMO1) デグレーダーです。 HB007 は SUMO1 のユビキチン化と分解を誘導し、in vivo での腫瘍増殖を抑制します。 HB007 は、脳、乳、結腸、および肺がんの研究に使用できます。

Products are for research use only. Not for human use. We do not sell to patients.

HB007 化学構造

Cas No.: 2387821-46-5

サイズ 価格 在庫数 個数
5 mg
$270.00
在庫あり
10 mg
$414.00
在庫あり
25 mg
$810.00
在庫あり
50 mg
$1,215.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

HB007 is a small ubiquitin-related modifier 1 (SUMO1) degrader. HB007 induces ubiquitination and degradation of SUMO1, resulting in reduced tumor growth in vivo. HB007 can be used for the research of brain, breast, colon, and lung cancers[1][2].

HB007 (compound 24) (0.1-100 μM) inhibits LN229 cell growth in a concentration-dependent manner t[1].HB007 (10-25 μM) reduces SUM01 conjugation and total protein levels of SUM01 but not SUM02/3 or UB in LN229 cells t[1].

HB007 (compound 24) (25-50 mg/kg; i.p. for 15 d) significantly suppresses tumor growth of colon and lung cancer but had no effect on the body weights of mice[1].

[1]. Bellail AC, et, al. Ubiquitination and degradation of SUMO1 by small-molecule degraders extends survival of mice with patient-derived tumors. Sci Transl Med. 2021 Oct 13;13(615):eabh1486.
[2]. BELLAIL A, et, al. Compositions and methods for treating cancer. WO2019217509A1.

レビュー

Review for HB007

Average Rating: 5 ★★★★★ (Based on Reviews and 1 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for HB007

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.